Tags

Type your tag names separated by a space and hit enter

Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Maturitas. 2001 Jul 25; 39(1):71-7.M

Abstract

OBJECTIVE

To determine the effect of raloxifene (RLX) and hormone replacement therapy (HRT) on non-high density lipoprotein cholesterol (non-HDL-C) levels and the apolipoprotein-B/apolipoprotein-A1 (apo-B/apo-A1) concentration ratio, markers of serum atherogenicity, in postmenopausal women.

METHODS

Three hundred and ninety healthy postmenopausal women aged 45-72 years were enrolled in a double-blind, randomized, placebo-controlled, parallel trial at eight outpatient sites in the United States. Women were randomly assigned to receive continuous combined HRT (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate), 60 or 120 mg/day raloxifene, or placebo for 6 months. Serum concentrations of non-HDL cholesterol and the apo-B/apo-A1 concentration ratio were measured in serum samples obtained at baseline and at 6 months of treatment.

RESULTS

At 6 months, non-HDL-C and apo-B/apo-A1 were significantly reduced by 60 mg/day RLX (10 and 11%, respectively), 120 mg/day RLX (9 and 12%, respectively) and HRT (10 and 12%, respectively), compared with placebo. The effect of all treatments to lower non-HDL-C and apo-B/apo-A1 was greatest in women with hypercholesterolemia (total-C>240 mg/dl) at baseline. Among women with undesirable (>160 mg/dl) non-HDL cholesterol at baseline, RLX and HRT lowered the percentage of these women remaining above this threshold after 6 months (placebo, 89%; 60 mg/day RLX, 61%; 120 mg/day RLX, 74%; HRT, 58%). Similar results were observed for women with high (>190 mg/dl) non-HDL cholesterol at baseline.

CONCLUSION

In healthy postmenopausal women, RLX and HRT lower serum non-HDL-C and apo-B/apo-A1, indicators of serum atherogenicity, to a similar extent.

Authors+Show Affiliations

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. anderson_pamela_w@lilly.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11451623

Citation

Anderson, P W., et al. "Effects of Raloxifene and Hormone Replacement Therapy On Markers of Serum Atherogenicity in Healthy Postmenopausal Women." Maturitas, vol. 39, no. 1, 2001, pp. 71-7.
Anderson PW, Cox DA, Sashegyi A, et al. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas. 2001;39(1):71-7.
Anderson, P. W., Cox, D. A., Sashegyi, A., Paul, S., Silfen, S. L., & Walsh, B. W. (2001). Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas, 39(1), 71-7.
Anderson PW, et al. Effects of Raloxifene and Hormone Replacement Therapy On Markers of Serum Atherogenicity in Healthy Postmenopausal Women. Maturitas. 2001 Jul 25;39(1):71-7. PubMed PMID: 11451623.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. AU - Anderson,P W, AU - Cox,D A, AU - Sashegyi,A, AU - Paul,S, AU - Silfen,S L, AU - Walsh,B W, PY - 2001/7/14/pubmed PY - 2001/8/24/medline PY - 2001/7/14/entrez SP - 71 EP - 7 JF - Maturitas JO - Maturitas VL - 39 IS - 1 N2 - OBJECTIVE: To determine the effect of raloxifene (RLX) and hormone replacement therapy (HRT) on non-high density lipoprotein cholesterol (non-HDL-C) levels and the apolipoprotein-B/apolipoprotein-A1 (apo-B/apo-A1) concentration ratio, markers of serum atherogenicity, in postmenopausal women. METHODS: Three hundred and ninety healthy postmenopausal women aged 45-72 years were enrolled in a double-blind, randomized, placebo-controlled, parallel trial at eight outpatient sites in the United States. Women were randomly assigned to receive continuous combined HRT (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate), 60 or 120 mg/day raloxifene, or placebo for 6 months. Serum concentrations of non-HDL cholesterol and the apo-B/apo-A1 concentration ratio were measured in serum samples obtained at baseline and at 6 months of treatment. RESULTS: At 6 months, non-HDL-C and apo-B/apo-A1 were significantly reduced by 60 mg/day RLX (10 and 11%, respectively), 120 mg/day RLX (9 and 12%, respectively) and HRT (10 and 12%, respectively), compared with placebo. The effect of all treatments to lower non-HDL-C and apo-B/apo-A1 was greatest in women with hypercholesterolemia (total-C>240 mg/dl) at baseline. Among women with undesirable (>160 mg/dl) non-HDL cholesterol at baseline, RLX and HRT lowered the percentage of these women remaining above this threshold after 6 months (placebo, 89%; 60 mg/day RLX, 61%; 120 mg/day RLX, 74%; HRT, 58%). Similar results were observed for women with high (>190 mg/dl) non-HDL cholesterol at baseline. CONCLUSION: In healthy postmenopausal women, RLX and HRT lower serum non-HDL-C and apo-B/apo-A1, indicators of serum atherogenicity, to a similar extent. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/11451623/Effects_of_raloxifene_and_hormone_replacement_therapy_on_markers_of_serum_atherogenicity_in_healthy_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(00)00224-3 DB - PRIME DP - Unbound Medicine ER -